How this shows up in interviews — Selling in life sciences & health tech (UK)

"How would you sell into an NHS trust?"

Start with the map, not the pitch:

find the clinical problem owner and win a champion;
multi-thread early to the CCIO/CIO, IG and procurement;
establish which budget and procurement route (framework, tender, or small direct award) the deal would travel;
arrive with the compliance pack (DTAC, DSPT, DCB0129, device status) ready.

Close by acknowledging the April–March budget cycle and a realistic 6–18 month timeline. The differentiator is sounding like someone who respects the process, not someone planning to hustle around it.

"What do you know about NHS procurement?"

Give the three routes — and say explicitly that thresholds change so you check rather than memorise:

frameworks with call-offs (name G-Cloud and NHS SBS);
competitive tenders via Find a Tender under the post-2023 regime;
below-threshold direct awards.

Then the trump card, if you built the section 9 asset: you have been tracking real award notices on Contracts Finder and Find a Tender in this company's category, so you can talk about what actual awards look like — which buyers, which suppliers, what values. That turns a textbook question into evidence; even a fortnight of genuine notice-reading puts you ahead of most candidates with sector CVs.

"How would you run a pilot that actually converts?"

Define pilotitis, then the four fixes:

written success criteria tied to metrics the buyer's committees value;
a named executive sponsor with a scheduled decision meeting;
the commercial path agreed before the pilot starts;
honest testing of deployment reality.

If anything in your past involved an evaluation run against pre-agreed criteria — a research project, a trial period, a structured comparison — anchor there; if not, the precision of the mechanism is itself your evidence. Naming the disease and prescribing the cure, unprompted, is what separates prepared candidates.

"You've never sold in healthcare. Why won't the learning curve sink you?"

Concede the true part fast — one sentence, no squirming — then split the curve in two.

The sales curve: point at whatever evidence of the craft you have (the fundamentals in modules 01–06, plus any persuasion-shaped experience — fundraising, recruitment, service work, a side business).
The domain curve: show you've attacked it deliberately, using your section 9 assets — study, a healthcare-adjacent project, a market tracker, published analysis.

Offer a 90-day-plan flavour: shadow deals, map the accounts, get fluent in the compliance gates. The interviewer isn't scoring the gap; they're scoring how you close gaps.

"What's the difference between selling software and selling CDMO/CRO services?" (CDMO/CRO business-development screens)

Software sells a product with a business case; CDMO/CRO BD sells capacity, expertise and trust in multi-year programmes, won through RFPs and bid-defence meetings where your scientists face theirs.

The BD role is qualification and orchestration — matching client programmes to real capabilities, building relationships ahead of need. Note the risk texture: client attrition happens when molecules fail, not just when service disappoints.

"How would you grow a territory of existing accounts?" (lab-products account-management interviews)

Say the quiet part: most growth is share-of-wallet in accounts already buying.

Start with install-base and spend analysis to find whitespace (accounts buying category A but not B).
Build a visit cadence weighted to growth potential.
Track grant cycles and university tender pipelines.
Keep distributor relationships coherent with direct ones.

It's an operating rhythm, not hero deals.

"What would you need to be careful about selling an AI diagnostic into the NHS?"

Regulatory status first: software as a medical device, what class, UKCA/CE position — and never let marketing claims outrun the registered intended use.

Then clinical safety (DCB0129 artefacts feeding the trust's DCB0160 work), IG/DPIA for patient data, and evidence proportionate to risk per NICE's evidence-standards thinking.

Add that AI-specific regulation is actively evolving at the MHRA, so you keep current — the right humility for any clinical-AI vendor's interview.

"Talk me through the stakeholders in a typical NHS deal."

Walk the cast:

clinical champion (your internal seller)
CCIO/CIO (workflow and technical estate)
IG/DPO and Caldicott Guardian (data)
procurement (the referee)
finance (mechanism-of-savings sceptic)
transformation team (delivery capacity)

Then the craft point: multi-thread from the start and help the champion build a case that survives each committee — you're arming an insider, not pitching a room.

Cheat sheet

Market physics: 6–24 month cycles · committee buying (no single economic buyer) · evidence proportionate to clinical risk · rational risk aversion · regulated products · NHS financial year Apr–Mar (be in next year's plan by spring; year-end money is a bonus, not a strategy).

NHS map: Trusts = secondary-care operating units, usually your customer. Primary care = GP practices/PCNs, volume motion. ICBs = regional budget-holders/commissioners (mergers ongoing — check count). NHS England → being absorbed into DHSC (verify status). NICE = evidence and cost-effectiveness gatekeeper (Evidence Standards Framework). MHRA = device regulator (SaMD/AI classification, UKCA/CE).

Stakeholder cast: clinical champion · CCIO/CIO · IG/DPO (+ Caldicott Guardian, DPIA) · procurement · finance · transformation. Multi-thread; arm the champion.

Procurement routes: frameworks (G-Cloud, NHS SBS, NHS Supply Chain) → call-offs/mini-competitions · tenders via Find a Tender (Procurement Act 2023 era; ITT/SQ; won pre-publication) · direct awards below thresholds (thresholds change — always look up).

Compliance gates: DTAC (NHS baseline assessment: clinical safety, data protection, security, interoperability, usability) · DSPT (annual data-security self-assessment) · DCB0129 (manufacturer clinical risk management + Clinical Safety Officer) / DCB0160 (deployer's mirror) · MHRA registration + UKCA/CE for software as a medical device.

Evidence ladder: case studies → pilots/POCs → health-economic analysis → peer-reviewed studies. Pilot conversion kit: written success criteria · named sponsor + scheduled decision · commercial path agreed up front · real-world deployment tested. Disease to name: pilotitis.

Pharma/biotech: map research → development → clinical ops → quality → regulatory → IT. GxP + CSV (GAMP, Part 11/Annex 11) = the validation burden; sell how you reduce it. Scientific credibility with users, business case with executives. CDMO/CRO BD = capacity + trust, RFPs and bid defences, programme deals.

Lab products (AM): territory routine is the job · share-of-wallet > new logos · install base drives consumables · university tenders/consortia + grant cycles · manage distributor channel coherence.

Pharma field sales: rep-to-clinician · ABPI Code (PMCPA-enforced) · ABPI exam required early in role · local formulary access via drug & therapeutics committees.

Your one-liner: name the gap in one sentence, then prove the preparation — credibility assets: a science degree at any level · healthcare-adjacent work or projects · a self-built market tracker over the public procurement record · published analysis. Never claim experience you don't have; claim unusual preparation.

References & further reading

Digital Technology Assessment Criteria (DTAC) — NHS England (NHS Transformation Directorate, transform.england.nhs.uk). The actual baseline assessment NHS buyers apply to digital health products; read the buyer-and-supplier guidance and the form itself — knowing what is in it, section by section, is table stakes for any NHS-facing sales interview.
Data Security and Protection Toolkit (DSPT) — NHS England (dsptoolkit.nhs.uk). The annual self-assessment for any organisation handling NHS patient data; skim the published assertion structure so you can discuss what compliance actually involves rather than just naming the acronym.
Evidence standards framework for digital health technologies — NICE (nice.org.uk). The clearest public statement of what evidence a technology of a given risk level needs — effectively the buyer's evidence checklist, and free to read.
Software and artificial intelligence (AI) as a medical device — MHRA guidance (gov.uk). The regulator's own account of when software is a medical device and where UK SaMD/AI regulation is heading; the antidote to second-hand summaries, and directly relevant to clinical-AI roles.
Digital transformation in the NHS — National Audit Office (2020). The most sober official account of why NHS digitisation has been slow, fragmented and underfunded — excellent background for understanding the buyer scepticism you will meet in every meeting.
Selling to the NHS: a how-to guide — Tussell (2022). A practical, data-led primer on NHS procurement from a public-contracts data company, with commentary from healthcare bid specialists; Tussell's market analyses pair naturally with the self-built market-tracking project section 9 recommends.
Health Service Journal (HSJ) — hsj.co.uk. The NHS management trade press: reading it is the fastest way to absorb how NHS leaders actually talk about money, performance and technology. Subscription-based, but even the free pieces teach the vocabulary.
The ABPI Code of Practice (2024 edition) — ABPI, administered by the PMCPA (pmcpa.org.uk). The primary text behind section 8 of this module; the PMCPA's published case rulings are instructive reading on how promotion rules bite in practice.
Find a Tender and Contracts Finder — GOV.UK. The primary public record of UK procurement — tender and award notices; the raw material for the market-tracking project in section 9 and the best free market intelligence available in this module's territory.